Biocept, Inc. (BIOC)
Stock Price Chart
Key Info
| Market Cap | 133.72M |
| Revenue (ttm) | 5.95M |
| Net Income (ttm) | -27.56M |
| Shares Out | 131.10M |
| EPS (ttm) | -0.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 12, 2020 |
| Last Price | $1.02 |
| Previous Close | $1.00 |
| Change ($) | 0.02 |
| Change (%) | 2.00% |
| Day's Open | 1.08 |
| Day's Range | 1.00 - 1.08 |
| Day's Volume | 13,443,263 |
| 52-Week Range | 0.21 - 1.30 |
More Stats
| Market Cap | 133.72M |
| Enterprise Value | 114.54M |
| Earnings Date (est) | Nov 5, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 131.10M |
| Float | 122.08M |
| EPS (basic) | -0.86 |
| EPS (diluted) | -0.74 |
| FCF / Share | -0.30 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 4.93M |
| Short Ratio | 0.30 |
| Short % of Float | 4.12% |
| Beta | 0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 22.47 |
| PB Ratio | 6.58 |
| Revenue | 5.95M |
| Operating Income | -23.38M |
| Net Income | -27.56M |
| Free Cash Flow | -23.80M |
| Net Cash | 19.18M |
| Net Cash / Share | 0.15 |
| Gross Margin | -91.57% |
| Operating Margin | -392.96% |
| Profit Margin | -463.60% |
| FCF Margin | -399.97% |
| ROA | -56.54% |
| ROE | -150.02% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.53 | 3.25 | 5.07 | 3.22 | 0.61 | 0.13 | 0.13 | 0.11 |
| Revenue Growth | 70.09% | -35.87% | 57.26% | 428.46% | 357.15% | -0.62% | 22.83% | - |
| Gross Profit | -5.45 | -6.80 | -4.28 | -3.70 | -3.99 | -2.04 | -2.20 | -1.09 |
| Operating Income | -23.06 | -24.26 | -21.17 | -18.03 | -16.41 | -13.87 | -7.94 | -10.50 |
| Net Income | -25.14 | -24.57 | -21.61 | -18.40 | -16.95 | -15.87 | -9.23 | -12.26 |
| Shares Outstanding | 20.66 | 2.80 | 0.92 | 0.32 | 0.18 | 0.04 | - | - |
| Earnings Per Share | -1.22 | -9.01 | -23.58 | -57.63 | -92.11 | -357.34 | -4,572.50 | -6,879.46 |
| Operating Cash Flow | -23.05 | -22.36 | -19.65 | -15.70 | -15.15 | -14.58 | -6.20 | -8.61 |
| Capital Expenditures | -0.74 | -0.15 | -1.40 | -0.45 | -0.17 | -0.39 | - | -0.01 |
| Free Cash Flow | -23.78 | -22.50 | -21.05 | -16.15 | -15.32 | -14.97 | -6.20 | -8.62 |
| Cash & Equivalents | 9.30 | 3.42 | 2.15 | 4.61 | 8.82 | 5.36 | 0.07 | 0.19 |
| Total Debt | 2.54 | 1.63 | 2.79 | 4.17 | 4.67 | 4.89 | 7.40 | 22.63 |
| Net Cash / Debt | 6.76 | 1.80 | -0.64 | 0.43 | 4.15 | 0.47 | -7.33 | -22.44 |
| Assets | 17.73 | 8.75 | 7.38 | 7.58 | 10.59 | 6.57 | 1.33 | 1.47 |
| Liabilities | 6.53 | 5.71 | 6.08 | 6.92 | 6.89 | 6.79 | 13.79 | 28.85 |
| Book Value | 11.20 | 3.04 | 1.30 | 0.66 | 3.69 | -0.22 | -12.46 | -27.38 |
Company Profile
Company Details
| Full Name | Biocept, Inc. |
| Country | United States |
| Employees | 88 |
| CEO | Michael W. Nall |
Stock Information
| Ticker Symbol | BIOC |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Laboratories & Research |
| Unique Identifier | NASDAQ: BIOC |
| IPO Date | February 5, 2014 |
Description
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.